There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LifeMD (LFMD – Research Report) and Dyne Therapeutics (DYN – Research Report) with bullish sentiments.
LifeMD (LFMD)
In a report released today, William Wood from B.Riley Financial reiterated a Buy rating on LifeMD, with a price target of $12.00. The company’s shares closed last Monday at $7.60.
According to TipRanks.com, Wood is a 1-star analyst with an average return of
Currently, the analyst consensus on LifeMD is a Strong Buy with an average price target of $13.25, representing a 68.6% upside. In a report issued on May 9, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Dyne Therapeutics (DYN)
Jefferies analyst Andrew Tsai maintained a Buy rating on Dyne Therapeutics today and set a price target of $42.00. The company’s shares closed last Monday at $33.89.
According to TipRanks.com, Tsai is a 3-star analyst with an average return of
Dyne Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.38, which is a 27.4% upside from current levels. In a report issued on May 5, Chardan Capital also maintained a Buy rating on the stock with a $31.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LFMD:
